Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension

Yvonne Dempsie, Neil MacRitchie, Kevin White, Ian Morecroft, Audrey F. Wright, Margaret Nilsen, Lynn Loughlin, Kirsty M. Mair, Margaret R. MacLean

Research output: Contribution to journalArticle

Abstract

Pulmonary arterial hypertension (PAH) occurs more frequently in women than men. Oestrogen and the oestrogen-metabolising enzyme cytochrome P450 1B1 (CYP1B1) play a role in the development of PAH. Anorectic drugs such as dexfenfluramine (Dfen) have been associated with the development of PAH. Dfen mediates PAH via a serotonergic mechanism and we have shown serotonin to up-regulate expression of CYP1B1 in human pulmonary artery smooth muscle cells (PASMCs). Thus here we assess the role of CYP1B1 in the development of Dfen-induced PAH.
Original languageEnglish
Pages (from-to)24-34
Number of pages11
JournalCardiovascular Research
Volume99
Issue number1
Early online date20 Mar 2013
DOIs
Publication statusPublished - Jul 2013

Keywords

  • arterial hypertension
  • oestrogen
  • anorectic drugs

Fingerprint Dive into the research topics of 'Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension'. Together they form a unique fingerprint.

  • Cite this

    Dempsie, Y., MacRitchie, N., White, K., Morecroft, I., Wright, A. F., Nilsen, M., Loughlin, L., Mair, K. M., & MacLean, M. R. (2013). Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovascular Research, 99(1), 24-34. https://doi.org/10.1093/cvr/cvt064